NasdaqGM:VCYTBiotechs
Veracyte (VCYT) Stock Sinks As Profit Strength Meets Reimbursement Doubt
Veracyte stock just dropped 22% to US$46.32, even though the quarter delivered what many long term investors say they want. Revenue reached US$150.3m and net income came in at US$25.5m, with adjusted earnings before interest, tax, depreciation and amortization at US$44m, equal to 29.2% of sales. That is a rich margin in diagnostics testing.
The short term verdict is clear on your screen. The longer term question is whether a business that now generates this level of profit and cash can...